Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

Adalimumab feasible for long-term control of hidradenitis suppurativa

22 Dec 2018

Continuous weekly administration of adalimumab (ADA) at 40 mg appears to be an adequate option for long-term control of moderate-to-severe hidradenitis suppurativa (HS), a recent study has shown.

Eighty-eight study participants were given ADA (median age 35.5 years; 63.6 percent female) of whom 63 either achieved HS clinical response (HiSCR) at week 12 or showed a 25-percent reduction in abscess and inflammatory nodule (AN) counts relative to baseline (responders plus partial responders [PRR]; median age 36.0 years; 65.1 percent female).

Results were generally persistent over time. The percentage of ADA-treated patients achieving HiSCR increased from 52.3 percent at week 12 to 62.5 percent at week 36. By week 168, this proportion was back down to 52.3 percent.

Similarly, there were improvements persistent over time in the counts of AN, draining fistula, inflammatory nodules and total fistula in both groups. The same was true for pain rating. The rate of flare was low and stable.

There was also a meaningful improvement in Dermatology Life Quality Index scores in both groups, which was maintained through week 72.

In terms of treatment safety, no adverse events of opportunistic infections were seen, except for oral candidiasis, over the mean exposure duration of 2.21 and 2.26 patient-years in the ADA-treated and PRR groups, respectively. Three serious infections were reported overall, with one case of pneumonia being probably related to the treatment.

The most common treatment-emergent adverse events included hidradenitis, headaches, upper respiratory tract infections, arthralgia, diarrhoea and dizziness, among others.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.